• 1. Blood contains two types of cancer-derived materials, circulating tumor cells and cell-free circulating tumor DNA, both of which are susceptible to detailed molecular analysis.
• Your Colleagues Responded
• A. True

  0%
• B. False

  0%

• 2. For which of the following clinical applications can liquid biopsies be used?
• Your Colleagues Responded
• A. Screening for presence of disease

  0%
• B. Patient stratification and therapy selection

  0%
• C. Monitoring treatment response

  0%
• D. Detection of minimal residual disease after surgery or recurrence

  0%
• E. All of the above

  0%

• 3. One of the largest studies investigating cancer mutations in liquid biopsies demonstrated that liquid biopsies identified cancer mutations in 85% of all advanced tumors, and in nearly half of all cases, the biomarkers were associated with an approved targeted drug.
• Your Colleagues Responded
• A. True

  0%
• B. False

  0%

• 4. Studies have failed to demonstrate that liquid biopsies can detect resistant mutations, such as the T790M mutation found in patients with lung cancer who are progressing on EGFR inhibitor therapy.
• Your Colleagues Responded
• A. True

  0%
• B. False

  0%

• 5. Most studies have demonstrated high concordance rates (eg, > 80%) between tumor and liquid biopsy for detection of cancer mutations.
• Your Colleagues Responded
• A. True

  0%
• B. False

  0%

• 6. Which of the following is not a challenge or limitation to the use of liquid biopsies?
• Your Colleagues Responded
• A. May potentially miss biomarkers expressed in the tumor

  0%
• B. More costly than tumor biopsy and analysis

  0%
• C. Test variability

  0%
• D. Lack of consensus in technical approaches of choice

  0%

• 7. Which of the following statements is not true? Liquid biopsies:
• Your Colleagues Responded
• A. are a noninvasive method for identification of tumor markers, either as an alternative for patients whose tissue is unable to be biopsied or as an adjunct to evaluate drug response.

  0%
• B. provide an accurate snapshot of the genomic landscape of the tumor, bypassing issues such as intratumor heterogeneity

  0%
• C. facilitate tumor DNA sequencing because DNA crosslinking does not occur, compared with tissue biopsies in which DNA is often preserved in formalin-fixed paraffin-embedded blocks

  0%
• D. are the current gold standard for molecular analysis to identify actionable mutations in all patients

  0%

• 8. The cobas EGFR Mutation Test v2 (Roche) was the first liquid biopsy test approved by the FDA.
• Your Colleagues Responded
• A. True

  0%
• B. False

  0%